EDUCATIONAL OVERVIEW
Pulmonary arterial hypertension (PAH) is a rare disease with significant consequences, including serious functional impairment and premature death. If left untreated, PAH is rapidly fatal. Fortunately, over the past decade, the knowledge and understanding of this disease has greatly expanded. Furthermore, the availability of effective and more convenient oral and inhaled medications has allowed clinicians to better individualize therapy to meet patient treatment goals. Though there is no cure for PAH, effective treatment can significantly slow disease progression and clinical worsening. Given the serious nature of this disease and its rapid progression, optimal management approaches are essential.

The Role of the Pharmacist
Optimal management of patients with PAH requires early detection and diagnosis followed by a patient-centered treatment plan. By increasing their competency, pharmacists can play an important role within the multidisciplinary team when encountering patients with this disease.

Given the complex and individualized nature of PAH therapy, pharmacists must have a full understanding of treatment algorithms, disease-specific therapies, and long-term monitoring recommendations based on evidence-based guidelines. As the armamentarium to treat PAH continues to expand, pharmacists must make efforts to stay informed of the latest finding in order to contribute to the optimal management of these patients.

TARGET AUDIENCE
This continuing pharmacy education activity is planned to meet the needs of pharmacists in a variety of practice settings, including large and small healthcare systems, outpatient clinics, managed care organizations, long-term care facilities, and academia. This program is designed for health-system pharmacists who are responsible for the safe and effective use of medications for the treatment of patients with PAH.

    LEARNING OBJECTIVES
Upon completing this activity, participants will be able to:
  • Differentiate the safety and efficacy among the various
    classes of medications used in the treatment of PAH
  • Utilize evidence-based guidelines to select appropriate
    therapy to meet individualized patient treatment goals
  • Optimize management decisions based on
    pathophysiology of PAH
  • Discuss the role of clinical pharmacists in the
    management of patients with PAH

EDUCATIONAL FORMAT
This webcast on demand is based on the CE Satellite Symposium
conducted at the 47th ASHP Midyear Clinical Meeting & Exhibition

The webcast on demand is divided into two episodes:

  • Episode 1: Utilizing Current Therapeutic Options
    and Treatment Algorithms
    to Optimize Outcomes
    David Badesch, MD
  • Episode 2: Individualizing Therapy to Meet Patient Goals: Recognizing the Pharmacist's Role
    James Coons, PharmD

Note: If you received credit for attending the live symposium by the same name, you are not eligible to apply for credit for this online version.

FACULTY

David B. Badesch, MD, FACP, FCCP
Professor of Medicine
Divisions of Pulmonary Sciences,
  Critical Care Medicine, and Cardiology
Clinical Director, Pulmonary Hypertension Center
University of Colorado at Denver and Health Sciences Center
Denver, CO

James C. Coons, PharmD, BCPS (AQ Cardiology)
Associate Professor
University of Pittsburgh School of Pharmacy
Cardiology Residency Program Director
Clinical Pharmacist, Cardiology
University of Pittsburgh Medical Center-Presbyterian Hospital
Pittsburgh, PA

 



 

Pharmacists
ACPE LogoCenter for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credits for participating in this activity.

ACPE UAN:  0473-9999-12-009-H01-P
Activity type: Knowledge-based

For questions regarding the accreditation of this activity, please contact us at info@jointsponsor.com


Method of Participation and Instruction for Credit

  1. Review the entire CE information including target audience, learning objectives, and disclosures.
  2. Review each episode.
  3. Complete the Post Test, Evaluation, and Credit Application Form.
  4. Please note that to receive credit you must achieve a score of at least 80%.
  5. Mail the completed Post Test, Evaluation, and Credit Application Form to Vemco MedEd, 245 US Highway 22, Suite 304, Bridgewater, NJ 08807 or fax to (908) 235-4222 or email to bhassid@vemcomeded.com.
  6. The information that you participated will be uploaded to CPE Monitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit http://www.nabp.net/.


Disclosure of Conflicts of Interest Policy

In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), Center for Independent Healthcare Education requires all faculty members and planning committee with an opportunity to affect the content of a continuing education activity to disclose any relevent financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.

Planning Committee Members
David B. Badesch, MD
James C. Coons, PharmD
Paul DeLisle
Marco P. Cicero, PhD
Maja Drenovac, PharmD

   

Disclosure of Financial Interest Summary
David B. Badesch, MD (Faculty/Planner) has relevant financial relationships with commercial interests as follows:

  • Advisory Board/Steering Committees: Actelion/CoTherix, Gilead/Myogen, Pfizer, United Therapeutics/Lung Rx, Lilly/ICOS, Bayer, Ikaria, Arena
  • Consultant: Actelion/CoTherix, Gilead/Myogen, Pfizer, United Therapeutics/Lung Rx, Lilly/ICOS, Bayer, Ikaria, Arena
  • Grant Recipient/Research Support: Actelion/CoTherix, Gilead/Myogen, Pfizer, United Therapeutics/Lung Rx, Lilly/ICOS, Novartis, Bayer, Ikaria, Arena

Dr. Badesch does not intend to discuss the off-label use of a product.

James C. Coons, PharmD (Faculty/Planner) has no relevant financial relationships with commercial interests. Dr. Coons does not intend to discuss the off-label use of a product.

No other speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

Content review confirmed that the content was developed in a fair, balanced manner, free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

 

Cosponsorship
This activity is jointly sponsored by Center for Independent Healthcare Education and Vemco MedEd.

 

Commercial Support
This activity is supported by an educational grant from Actelion Pharmaceuticals, US, Inc.

Actelion Logo

Fee
There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any "pop-up blocker" features.

Software/Hardware
Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from Adobe.com)
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from Adobe.com)

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to info@vemcomeded.com.

Copyright Statement
Copyright© 2012 - 2013 Vemco MedEd, LLC. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy

http://www.vemcomeded.com/privacy.asp
 


 

Start Activity

By clicking on an Episode,
I acknowledge that I have
read the entire CE information.

 

Please take a few moments to
take the Pre-Activity Survey.

Episode 1 Episode 2